Finding studies
Finding studies
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.